BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Stem Cells » iPS Cells » Page 2

Implant Therapeutics To Engineer iPSC-MSC Cells Containing panCELLa’s Technologies

January 13, 2021 By Cade Hildreth (CEO)

Implant Therapeutics

TORONTO, Jan. 8, 2021– panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.

Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa’s FailSafe™ and induced Allogeneic Cell Tolerance (iACT Stealth Cell™) technologies.  These iPSC MSC cells are hypo-immunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. [Read more…]

Filed Under: iPS Cells, Press Releases

Burgeoning Number of iPSC Therapies To Be Tested in Clinical Trials

January 9, 2021 By Cade Hildreth (CEO)

iPSC therapies

Therapeutic applications of induced pluripotent stem cells (iPSCs) have surged in recent years. Since the creation of human iPSCs in 2007, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2014. From 2014 to present, additional trials and physician-led studies employing human iPSC-derived cell types have been initiated across multiple geographies worldwide. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: iPS cells

Evotec Achieves Milestone within iPSC-Based Neuroscience Partnership with BMS

January 9, 2021 By Cade Hildreth (CEO)

Evotec iPSC neuroscience partnership BMS

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry.

HAMBURG, GERMANY / January 5, 2021 — Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced that the Company has received a US $6 million payment from Bristol Myers Squibb Company (NYSE: BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. [Read more…]

Filed Under: iPS Cells, Press Releases

Spinogenix Secures DOD Grant To Study Lead Compound in hiPSCs from Patients with ALS

January 8, 2021 By Cade Hildreth (CEO)

Spinogenix hiPSCs for ALS

Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)

SAN DIEGO, Calif., Jan. 05, 2021 — Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it will be collaborating with Dr. Rita Sattler at the Barrow Neurological Institute and Dr. Justin Ichida at the USC Keck School of Medicine on a grant awarded from the U.S. Department of Defense’s (“DOD”) Congressionally Directed Medical Research Programs (“CDMRP”) to evaluate its lead development candidate in ALS. [Read more…]

Filed Under: iPS Cells, Press Releases Tagged With: iPS cells

iPS Cell Therapy: Is Japan the Market Leader?

January 7, 2021 By Cade Hildreth (CEO)

Although there are key players in multiple geographies worldwide, Japan has positioned itself as a hub for induced pluripotent stem cell (iPS cell) technology. iPS cells are made by reprogramming adult cells back into an embryonic-like state. Derived from skin or blood cells, they are not controversial.

[Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: cynata therapeutics, FUJIFILM, iPS cells, iPSC, Japan

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 48
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297

Featured Posts

CellSource

Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source’s Scientific Advisory Board

Feature | Exosome Companies | Exosome Companies | Tiny Exosomes, Enormous Potential

List of Exosome Companies: Tiny Packages, Enormous Potential

Dr. John Sessions

The American Academy of Stem Cell Physicians Pays Tribute to Dr. John Sessions, “Everyone’s Teacher”

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.